C
Amgen Inc.
AMGN
$307.31
$7.012.33%
C
Hold
5/7/2024Downgrade
Amgen Inc. (AMGN) was downgraded to C from C+ on 5/7/2024 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.4247 to -$0.2108, net income declined 114.73% from $767M to -$113M, and total revenue declined 9.14% from $8.2B to $7.45B.
Amgen Inc. (AMGN) was downgraded to C from C+ on 5/7/2024 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $1.4247 to -$0.2108, net income declined 114.73% from $767M to -$113M, and total revenue declined 9.14% from $8.2B to $7.45B.
C
Hold
5/2/2024Downgrade
Amgen Inc. (AMGN) was downgraded to C+ from B- on 5/2/2024 due to a decline in the total return index, efficiency index and growth index.
Amgen Inc. (AMGN) was downgraded to C+ from B- on 5/2/2024 due to a decline in the total return index, efficiency index and growth index.
B
Buy
3/11/2024Upgraded
Amgen Inc. (AMGN) was upgraded to B- from C+ on 3/11/2024 due to an increase in the volatility index, valuation index and dividend index.
Amgen Inc. (AMGN) was upgraded to B- from C+ on 3/11/2024 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
2/15/2024Downgrade
Amgen Inc. (AMGN) was downgraded to C+ from B- on 2/15/2024 due to a substantial decline in the growth index, valuation index and solvency index. Operating cash flow declined 80.51% from $2.76B to $538M, EBIT declined 75.15% from $2.69B to $668M, and the quick ratio declined from 2.41 to 1.03.
Amgen Inc. (AMGN) was downgraded to C+ from B- on 2/15/2024 due to a substantial decline in the growth index, valuation index and solvency index. Operating cash flow declined 80.51% from $2.76B to $538M, EBIT declined 75.15% from $2.69B to $668M, and the quick ratio declined from 2.41 to 1.03.
B
Buy
11/3/2023Downgrade
Amgen Inc. (AMGN) was downgraded to B- from B on 11/3/2023 due to a noticeable decline in the growth index, efficiency index and valuation index. Operating cash flow declined 32.83% from $4.11B to $2.76B, EBIT declined 1.39% from $2.73B to $2.69B, and total revenue declined 1.19% from $6.99B to $6.9B.
Amgen Inc. (AMGN) was downgraded to B- from B on 11/3/2023 due to a noticeable decline in the growth index, efficiency index and valuation index. Operating cash flow declined 32.83% from $4.11B to $2.76B, EBIT declined 1.39% from $2.73B to $2.69B, and total revenue declined 1.19% from $6.99B to $6.9B.
B
Buy
10/19/2023Upgraded
Amgen Inc. (AMGN) was upgraded to B from B- on 10/19/2023 due to an increase in the total return index and volatility index.
Amgen Inc. (AMGN) was upgraded to B from B- on 10/19/2023 due to an increase in the total return index and volatility index.
B
Buy
9/18/2023Upgraded
Amgen Inc. (AMGN) was upgraded to B- from C+ on 9/18/2023 due to an increase in the total return index and volatility index.
Amgen Inc. (AMGN) was upgraded to B- from C+ on 9/18/2023 due to an increase in the total return index and volatility index.
C
Hold
8/31/2023Upgraded
Amgen Inc. (AMGN) was upgraded to C+ from C on 8/31/2023 due to a substantial increase in the growth index, volatility index and solvency index. Operating cash flow increased 286.18% from $1.06B to $4.11B, EBIT increased 31.88% from $2.07B to $2.73B, and debt to equity declined from 11.52 to 9.08.
Amgen Inc. (AMGN) was upgraded to C+ from C on 8/31/2023 due to a substantial increase in the growth index, volatility index and solvency index. Operating cash flow increased 286.18% from $1.06B to $4.11B, EBIT increased 31.88% from $2.07B to $2.73B, and debt to equity declined from 11.52 to 9.08.
C
Hold
5/19/2023Downgrade
Amgen Inc. (AMGN) was downgraded to C from C+ on 5/19/2023 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 59.83% from $2.65B to $1.06B, total revenue declined 10.73% from $6.84B to $6.11B, and EBIT declined 6.17% from $2.2B to $2.07B.
Amgen Inc. (AMGN) was downgraded to C from C+ on 5/19/2023 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 59.83% from $2.65B to $1.06B, total revenue declined 10.73% from $6.84B to $6.11B, and EBIT declined 6.17% from $2.2B to $2.07B.
C
Hold
4/26/2023Downgrade
Amgen Inc. (AMGN) was downgraded to C+ from B- on 4/26/2023 due to a decline in the volatility index, valuation index and total return index.
Amgen Inc. (AMGN) was downgraded to C+ from B- on 4/26/2023 due to a decline in the volatility index, valuation index and total return index.
B
Buy
3/29/2023Upgraded
Amgen Inc. (AMGN) was upgraded to B- from C+ on 3/29/2023 due to an increase in the volatility index, valuation index and dividend index.
Amgen Inc. (AMGN) was upgraded to B- from C+ on 3/29/2023 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
2/24/2023Downgrade
Amgen Inc. (AMGN) was downgraded to C+ from B- on 2/24/2023 due to a decline in the total return index, volatility index and solvency index.
Amgen Inc. (AMGN) was downgraded to C+ from B- on 2/24/2023 due to a decline in the total return index, volatility index and solvency index.
B
Buy
2/10/2023Downgrade
Amgen Inc. (AMGN) was downgraded to B- from B on 2/10/2023 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from $3.98 to $2.9942, EBIT declined 17.34% from $2.67B to $2.2B, and operating cash flow declined 11.05% from $2.98B to $2.65B.
Amgen Inc. (AMGN) was downgraded to B- from B on 2/10/2023 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from $3.98 to $2.9942, EBIT declined 17.34% from $2.67B to $2.2B, and operating cash flow declined 11.05% from $2.98B to $2.65B.
B
Buy
11/7/2022Upgraded
Amgen Inc. (AMGN) was upgraded to B from B- on 11/7/2022 due to a major increase in the growth index, total return index and solvency index. Earnings per share increased from $2.45 to $3.98, operating cash flow increased 54.3% from $1.93B to $2.98B, and debt to equity declined from 15.1 to 10.6.
Amgen Inc. (AMGN) was upgraded to B from B- on 11/7/2022 due to a major increase in the growth index, total return index and solvency index. Earnings per share increased from $2.45 to $3.98, operating cash flow increased 54.3% from $1.93B to $2.98B, and debt to equity declined from 15.1 to 10.6.
B
Buy
9/30/2022Downgrade
Amgen Inc. (AMGN) was downgraded to B- from B on 9/30/2022 due to a noticeable decline in the total return index.
Amgen Inc. (AMGN) was downgraded to B- from B on 9/30/2022 due to a noticeable decline in the total return index.
B
Buy
8/9/2022Upgraded
Amgen Inc. (AMGN) was upgraded to B from B- on 8/9/2022 due to a large increase in the growth index, valuation index and total return index. Total revenue increased 5.71% from $6.24B to $6.59B.
Amgen Inc. (AMGN) was upgraded to B from B- on 8/9/2022 due to a large increase in the growth index, valuation index and total return index. Total revenue increased 5.71% from $6.24B to $6.59B.
B
Buy
7/13/2022Upgraded
Amgen Inc. (AMGN) was upgraded to B- from C+ on 7/13/2022 due to a noticeable increase in the total return index, volatility index and dividend index.
Amgen Inc. (AMGN) was upgraded to B- from C+ on 7/13/2022 due to a noticeable increase in the total return index, volatility index and dividend index.
C
Hold
3/15/2022Upgraded
Amgen Inc. (AMGN) was upgraded to C+ from C on 3/15/2022 due to an increase in the volatility index and total return index.
Amgen Inc. (AMGN) was upgraded to C+ from C on 3/15/2022 due to an increase in the volatility index and total return index.
C
Hold
2/23/2022Downgrade
Amgen Inc. (AMGN) was downgraded to C from C+ on 2/23/2022 due to a major decline in the growth index and solvency index. Debt to equity increased from 4.57 to 4.99, the quick ratio declined from 1.19 to 1.14, and EBIT declined 0.97% from $2.38B to $2.36B.
Amgen Inc. (AMGN) was downgraded to C from C+ on 2/23/2022 due to a major decline in the growth index and solvency index. Debt to equity increased from 4.57 to 4.99, the quick ratio declined from 1.19 to 1.14, and EBIT declined 0.97% from $2.38B to $2.36B.
C
Hold
1/11/2022Upgraded
Amgen Inc. (AMGN) was upgraded to C+ from C on 1/11/2022 due to an increase in the volatility index and total return index.
Amgen Inc. (AMGN) was upgraded to C+ from C on 1/11/2022 due to an increase in the volatility index and total return index.
C
Hold
12/23/2021Downgrade
Amgen Inc. (AMGN) was downgraded to C from C+ on 12/23/2021 due to a decline in the total return index, valuation index and dividend index.
Amgen Inc. (AMGN) was downgraded to C from C+ on 12/23/2021 due to a decline in the total return index, valuation index and dividend index.
C
Hold
12/8/2021Upgraded
Amgen Inc. (AMGN) was upgraded to C+ from C on 12/8/2021 due to an increase in the valuation index, volatility index and dividend index.
Amgen Inc. (AMGN) was upgraded to C+ from C on 12/8/2021 due to an increase in the valuation index, volatility index and dividend index.
C
Hold
11/22/2021Downgrade
Amgen Inc. (AMGN) was downgraded to C from C+ on 11/22/2021 due to a decline in the volatility index and total return index.
Amgen Inc. (AMGN) was downgraded to C from C+ on 11/22/2021 due to a decline in the volatility index and total return index.
C
Hold
11/4/2021Upgraded
Amgen Inc. (AMGN) was upgraded to C+ from C on 11/4/2021 due to an increase in the growth index. Earnings per share increased from $0.8098 to $3.31, operating cash flow increased 25.22% from $1.93B to $2.42B, and total revenue increased 2.76% from $6.53B to $6.71B.
Amgen Inc. (AMGN) was upgraded to C+ from C on 11/4/2021 due to an increase in the growth index. Earnings per share increased from $0.8098 to $3.31, operating cash flow increased 25.22% from $1.93B to $2.42B, and total revenue increased 2.76% from $6.53B to $6.71B.
C
Hold
11/3/2021Downgrade
Amgen Inc. (AMGN) was downgraded to C from C+ on 11/3/2021 due to a decline in the volatility index and total return index.
Amgen Inc. (AMGN) was downgraded to C from C+ on 11/3/2021 due to a decline in the volatility index and total return index.
C
Hold
9/24/2021Downgrade
Amgen Inc. (AMGN) was downgraded to C+ from B- on 9/24/2021 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from $2.83 to $0.8098, the quick ratio declined from 1.16 to 0.86, and debt to equity increased from 3.5 to 3.98.
Amgen Inc. (AMGN) was downgraded to C+ from B- on 9/24/2021 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from $2.83 to $0.8098, the quick ratio declined from 1.16 to 0.86, and debt to equity increased from 3.5 to 3.98.
B
Buy
8/4/2021Downgrade
Amgen Inc. (AMGN) was downgraded to B- from B on 8/4/2021 due to a decline in the valuation index, growth index and volatility index. Total revenue declined 11.05% from $6.63B to $5.9B, and operating cash flow declined 2.28% from $2.15B to $2.1B.
Amgen Inc. (AMGN) was downgraded to B- from B on 8/4/2021 due to a decline in the valuation index, growth index and volatility index. Total revenue declined 11.05% from $6.63B to $5.9B, and operating cash flow declined 2.28% from $2.15B to $2.1B.
B
Buy
11/9/2020Upgraded
Amgen Inc. (AMGN) was upgraded to B from B- on 11/9/2020 due to a noticeable increase in the growth index, valuation index and dividend index. Operating cash flow increased 18.51% from $2.84B to $3.37B, earnings per share increased from $3.05 to $3.43, and EBIT increased 5.6% from $2.32B to $2.45B.
Amgen Inc. (AMGN) was upgraded to B from B- on 11/9/2020 due to a noticeable increase in the growth index, valuation index and dividend index. Operating cash flow increased 18.51% from $2.84B to $3.37B, earnings per share increased from $3.05 to $3.43, and EBIT increased 5.6% from $2.32B to $2.45B.
B
Buy
10/22/2020Downgrade
Amgen Inc. (AMGN) was downgraded to B- from B on 10/22/2020 due to a noticeable decline in the total return index.
Amgen Inc. (AMGN) was downgraded to B- from B on 10/22/2020 due to a noticeable decline in the total return index.
B
Buy
10/7/2020Upgraded
Amgen Inc. (AMGN) was upgraded to B from B- on 10/7/2020 due to an increase in the volatility index.
Amgen Inc. (AMGN) was upgraded to B from B- on 10/7/2020 due to an increase in the volatility index.
B
Buy
8/17/2020Downgrade
Amgen Inc. (AMGN) was downgraded to B- from B on 8/17/2020 due to a noticeable decline in the total return index, volatility index and valuation index.
Amgen Inc. (AMGN) was downgraded to B- from B on 8/17/2020 due to a noticeable decline in the total return index, volatility index and valuation index.
B
Buy
7/6/2020Upgraded
Amgen Inc. (AMGN) was upgraded to B from B- on 7/6/2020 due to a substantial increase in the total return index.
Amgen Inc. (AMGN) was upgraded to B from B- on 7/6/2020 due to a substantial increase in the total return index.
B
Buy
5/18/2020Downgrade
Amgen Inc. (AMGN) was downgraded to B- from B on 5/18/2020 due to a noticeable decline in the valuation index, growth index and dividend index. Operating cash flow declined 15.12% from $2.51B to $2.13B, and total revenue declined 0.58% from $6.2B to $6.16B.
Amgen Inc. (AMGN) was downgraded to B- from B on 5/18/2020 due to a noticeable decline in the valuation index, growth index and dividend index. Operating cash flow declined 15.12% from $2.51B to $2.13B, and total revenue declined 0.58% from $6.2B to $6.16B.
B
Buy
9/5/2019Upgraded
Amgen Inc. (AMGN) was upgraded to B from B- on 9/5/2019 due to an increase in the volatility index, total return index and solvency index.
Amgen Inc. (AMGN) was upgraded to B from B- on 9/5/2019 due to an increase in the volatility index, total return index and solvency index.
B
Buy
8/13/2019Upgraded
Amgen Inc. (AMGN) was upgraded to B- from C+ on 8/13/2019 due to an increase in the volatility index, growth index and solvency index. Earnings per share increased from $3.18 to $3.57, EBIT increased 8.33% from $2.47B to $2.68B, and debt to equity declined from 3.06 to 2.85.
Amgen Inc. (AMGN) was upgraded to B- from C+ on 8/13/2019 due to an increase in the volatility index, growth index and solvency index. Earnings per share increased from $3.18 to $3.57, EBIT increased 8.33% from $2.47B to $2.68B, and debt to equity declined from 3.06 to 2.85.
C
Hold
7/12/2019Downgrade
Amgen Inc. (AMGN) was downgraded to C+ from B- on 7/12/2019 due to a decline in the valuation index, dividend index and total return index.
Amgen Inc. (AMGN) was downgraded to C+ from B- on 7/12/2019 due to a decline in the valuation index, dividend index and total return index.
B
Buy
6/12/2019Upgraded
Amgen Inc. (AMGN) was upgraded to B- from C+ on 6/12/2019 due to an increase in the volatility index.
Amgen Inc. (AMGN) was upgraded to B- from C+ on 6/12/2019 due to an increase in the volatility index.
C
Hold
5/28/2019Downgrade
Amgen Inc. (AMGN) was downgraded to C+ from B- on 5/28/2019 due to a substantial decline in the growth index, volatility index and total return index. Operating cash flow declined 42.24% from $3.19B to $1.85B, total revenue declined 10.8% from $6.23B to $5.56B, and EBIT declined 9.05% from $2.72B to $2.47B.
Amgen Inc. (AMGN) was downgraded to C+ from B- on 5/28/2019 due to a substantial decline in the growth index, volatility index and total return index. Operating cash flow declined 42.24% from $3.19B to $1.85B, total revenue declined 10.8% from $6.23B to $5.56B, and EBIT declined 9.05% from $2.72B to $2.47B.
B
Buy
5/1/2019Downgrade
Amgen Inc. (AMGN) was downgraded to B- from B on 5/1/2019 due to a noticeable decline in the volatility index and total return index.
Amgen Inc. (AMGN) was downgraded to B- from B on 5/1/2019 due to a noticeable decline in the volatility index and total return index.
B
Buy
2/15/2019Upgraded
Amgen Inc. (AMGN) was upgraded to B from C on 2/15/2019 due to a significant increase in the valuation index, growth index and volatility index. Total revenue increased 5.52% from $5.9B to $6.23B, earnings per share increased from $2.86 to $3.0075, and EBIT increased 2.68% from $2.65B to $2.72B.
Amgen Inc. (AMGN) was upgraded to B from C on 2/15/2019 due to a significant increase in the valuation index, growth index and volatility index. Total revenue increased 5.52% from $5.9B to $6.23B, earnings per share increased from $2.86 to $3.0075, and EBIT increased 2.68% from $2.65B to $2.72B.
C
Hold
2/16/2018Downgrade
Amgen Inc. (AMGN) was downgraded to C from B on 2/16/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $2.76 to -$5.8927, net income declined 310.98% from $2.02B to -$4.26B, and operating cash flow declined 12.8% from $3.45B to $3.01B.
Amgen Inc. (AMGN) was downgraded to C from B on 2/16/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $2.76 to -$5.8927, net income declined 310.98% from $2.02B to -$4.26B, and operating cash flow declined 12.8% from $3.45B to $3.01B.
B
Buy
2/22/2017Upgraded
Amgen Inc. (AMGN) was upgraded to B from B- on 2/22/2017 due to an increase in the growth index, total return index and efficiency index. Operating cash flow increased 16.45% from $2.66B to $3.1B, and total revenue increased 2.65% from $5.81B to $5.97B.
Amgen Inc. (AMGN) was upgraded to B from B- on 2/22/2017 due to an increase in the growth index, total return index and efficiency index. Operating cash flow increased 16.45% from $2.66B to $3.1B, and total revenue increased 2.65% from $5.81B to $5.97B.
B
Buy
1/3/2017Downgrade
Amgen Inc. (AMGN) was downgraded to B- from B on 1/3/2017 due to a noticeable decline in the total return index and volatility index.
Amgen Inc. (AMGN) was downgraded to B- from B on 1/3/2017 due to a noticeable decline in the total return index and volatility index.
B
Buy
11/2/2016Downgrade
Amgen Inc. (AMGN) was downgraded to B from B+ on 11/2/2016 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 0.56% from $2.68B to $2.66B.
Amgen Inc. (AMGN) was downgraded to B from B+ on 11/2/2016 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 0.56% from $2.68B to $2.66B.
B
Buy
10/24/2016Downgrade
Amgen Inc. (AMGN) was downgraded to B+ from A- on 10/24/2016 due to a noticeable decline in the total return index and volatility index.
Amgen Inc. (AMGN) was downgraded to B+ from A- on 10/24/2016 due to a noticeable decline in the total return index and volatility index.
A
Buy
10/20/2016Downgrade
Amgen Inc. (AMGN) was downgraded to A- from A on 10/20/2016 due to a decline in the total return index and volatility index.
Amgen Inc. (AMGN) was downgraded to A- from A on 10/20/2016 due to a decline in the total return index and volatility index.
A
Buy
9/7/2016Upgraded
Amgen Inc. (AMGN) was upgraded to A from A- on 9/7/2016 due to an increase in the total return index, valuation index and volatility index.
Amgen Inc. (AMGN) was upgraded to A from A- on 9/7/2016 due to an increase in the total return index, valuation index and volatility index.
A
Buy
8/22/2016Upgraded
Amgen Inc. (AMGN) was upgraded to A- from B+ on 8/22/2016 due to a noticeable increase in the total return index and volatility index.
Amgen Inc. (AMGN) was upgraded to A- from B+ on 8/22/2016 due to a noticeable increase in the total return index and volatility index.
B
Buy
8/5/2016Upgraded
Amgen Inc. (AMGN) was upgraded to B+ from B on 8/5/2016 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 39.79% from $1.92B to $2.68B, and total revenue increased 2.91% from $5.53B to $5.69B.
Amgen Inc. (AMGN) was upgraded to B+ from B on 8/5/2016 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 39.79% from $1.92B to $2.68B, and total revenue increased 2.91% from $5.53B to $5.69B.
B
Buy
3/11/2016Downgrade
Amgen Inc. (AMGN) was downgraded to B from B+ on 3/11/2016 due to a major decline in the volatility index, growth index and total return index. Operating cash flow declined 28.32% from $2.87B to $2.06B, EBIT declined 14.83% from $2.36B to $2.01B, and total revenue declined 3.27% from $5.72B to $5.54B.
Amgen Inc. (AMGN) was downgraded to B from B+ on 3/11/2016 due to a major decline in the volatility index, growth index and total return index. Operating cash flow declined 28.32% from $2.87B to $2.06B, EBIT declined 14.83% from $2.36B to $2.01B, and total revenue declined 3.27% from $5.72B to $5.54B.
B
Buy
1/21/2016Downgrade
Amgen Inc. (AMGN) was downgraded to B+ from A- on 1/21/2016 due to a major decline in the volatility index and total return index.
Amgen Inc. (AMGN) was downgraded to B+ from A- on 1/21/2016 due to a major decline in the volatility index and total return index.
A
Buy
3/9/2015Downgrade
Amgen Inc. (AMGN) was downgraded to A- from A on 3/9/2015 due to a noticeable decline in the total return index, valuation index and volatility index.
Amgen Inc. (AMGN) was downgraded to A- from A on 3/9/2015 due to a noticeable decline in the total return index, valuation index and volatility index.
A
Buy
2/20/2015Upgraded
Amgen Inc. (AMGN) was upgraded to A from A- on 2/20/2015 due to a noticeable increase in the volatility index, growth index and valuation index. Total revenue increased 5.96% from $5.03B to $5.33B, and earnings per share increased from $1.61 to $1.6822.
Amgen Inc. (AMGN) was upgraded to A from A- on 2/20/2015 due to a noticeable increase in the volatility index, growth index and valuation index. Total revenue increased 5.96% from $5.03B to $5.33B, and earnings per share increased from $1.61 to $1.6822.
A
Buy
1/12/2015Downgrade
Amgen Inc. (AMGN) was downgraded to A- from A on 1/12/2015 due to a decline in the total return index.
Amgen Inc. (AMGN) was downgraded to A- from A on 1/12/2015 due to a decline in the total return index.
A
Buy
11/19/2014Upgraded
Amgen Inc. (AMGN) was upgraded to A from A- on 11/19/2014 due to a large increase in the total return index and volatility index.
Amgen Inc. (AMGN) was upgraded to A from A- on 11/19/2014 due to a large increase in the total return index and volatility index.
A
Buy
10/31/2014Downgrade
Amgen Inc. (AMGN) was downgraded to A- from A+ on 10/31/2014 due to a major decline in the growth index, volatility index and valuation index. Earnings per share declined from $2.01 to $1.61, EBIT declined 8.2% from $1.94B to $1.78B, and total revenue declined 2.88% from $5.18B to $5.03B.
Amgen Inc. (AMGN) was downgraded to A- from A+ on 10/31/2014 due to a major decline in the growth index, volatility index and valuation index. Earnings per share declined from $2.01 to $1.61, EBIT declined 8.2% from $1.94B to $1.78B, and total revenue declined 2.88% from $5.18B to $5.03B.
A
Buy
10/1/2014Upgraded
Amgen Inc. (AMGN) was upgraded to A+ from A on 10/1/2014 due to a large increase in the total return index and volatility index.
Amgen Inc. (AMGN) was upgraded to A+ from A on 10/1/2014 due to a large increase in the total return index and volatility index.
A
Buy
8/7/2014Upgraded
Amgen Inc. (AMGN) was upgraded to A from A- on 8/7/2014 due to a major increase in the growth index, solvency index and efficiency index. Operating cash flow increased 95.01% from $1.14B to $2.23B, net income increased 44.18% from $1.07B to $1.55B, and earnings per share increased from $1.4 to $2.01.
Amgen Inc. (AMGN) was upgraded to A from A- on 8/7/2014 due to a major increase in the growth index, solvency index and efficiency index. Operating cash flow increased 95.01% from $1.14B to $2.23B, net income increased 44.18% from $1.07B to $1.55B, and earnings per share increased from $1.4 to $2.01.
A
Buy
5/5/2014Downgrade
Amgen Inc. (AMGN) was downgraded to A- from A on 5/5/2014 due to a decline in the total return index, volatility index and valuation index.
Amgen Inc. (AMGN) was downgraded to A- from A on 5/5/2014 due to a decline in the total return index, volatility index and valuation index.
A
Buy
4/8/2014Upgraded
Amgen Inc. (AMGN) was upgraded to A from A- on 4/8/2014 due to a major increase in the volatility index and total return index.
Amgen Inc. (AMGN) was upgraded to A from A- on 4/8/2014 due to a major increase in the volatility index and total return index.
NASDAQ
05/08/2024 4:00PM Eastern
Quotes delayed
